• Je něco špatně v tomto záznamu ?

Adult growth hormone deficiency in CEE region: Heterogeneity of the patient pathway

I. Shimon, C. Badiu, A. Bossowski, M. Doknic, I. Dzivite-Krisane, V. Hána, J. Kollerova, E. Natchev, M. Pfeifer, N. Szũcs, J. Hey-Hadavi, R. Gomez,

. 2019 ; 46-47 (-) : 44-49. [pub] 20190607

Jazyk angličtina

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006218

OBJECTIVES: Adult growth hormone deficiency (AGHD) is a rare disease characterised by abnormal body composition, reduced strength and exercise capacity and impaired psychological wellbeing. An advisory board of leading Central and Eastern European (CEE) endocrinologists was assembled to gain insights into the status of AGHD care in the CEE region. Topics of discussion included the position of adult hypopituitarism/AGHD in health system priorities, availability and affordability of treatments, awareness of AGHD, practice guidelines used in CEE countries and provisions for long-term care of patients. DESIGN: Prior to the meeting, the advisors were asked to summarise, using an itemised survey questionnaire, the usual standards of care for patients with AGHD in their country. At the meeting, the panel of experts discussed the findings and thereby elucidated similarities and differences among CEE countries; these were compared with international guideline-recommended practices for AGHD. RESULTS: All CEE countries involved reported having some type of infrastructure in place for care of patients with GHD transitioning from adolescence to adulthood. Most countries reported having at least one specialist centre for patients with AGHD. The main variations across the region included initial entry into healthcare systems, tests required to confirm AGHD diagnosis and medication reimbursement by health authorities. Most CEE countries relied on international society-led guidelines, while some countries have developed national guidelines. CONCLUSION: The CEE Adult Endocrinology Advisory Board meeting recognised considerable diversity in the care and patient pathways for AGHD across CEE countries. Additional work is needed to optimise care of patients with AGHD in the CEE region.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006218
003      
CZ-PrNML
005      
20200525140555.0
007      
ta
008      
200511s2019 stk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ghir.2019.06.001 $2 doi
035    __
$a (PubMed)31234055
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a stk
100    1_
$a Shimon, Ilan $u Rabin Medical Center, Petah Tiqva, Israel. Electronic address: Ilanshi@clalit.org.il.
245    10
$a Adult growth hormone deficiency in CEE region: Heterogeneity of the patient pathway / $c I. Shimon, C. Badiu, A. Bossowski, M. Doknic, I. Dzivite-Krisane, V. Hána, J. Kollerova, E. Natchev, M. Pfeifer, N. Szũcs, J. Hey-Hadavi, R. Gomez,
520    9_
$a OBJECTIVES: Adult growth hormone deficiency (AGHD) is a rare disease characterised by abnormal body composition, reduced strength and exercise capacity and impaired psychological wellbeing. An advisory board of leading Central and Eastern European (CEE) endocrinologists was assembled to gain insights into the status of AGHD care in the CEE region. Topics of discussion included the position of adult hypopituitarism/AGHD in health system priorities, availability and affordability of treatments, awareness of AGHD, practice guidelines used in CEE countries and provisions for long-term care of patients. DESIGN: Prior to the meeting, the advisors were asked to summarise, using an itemised survey questionnaire, the usual standards of care for patients with AGHD in their country. At the meeting, the panel of experts discussed the findings and thereby elucidated similarities and differences among CEE countries; these were compared with international guideline-recommended practices for AGHD. RESULTS: All CEE countries involved reported having some type of infrastructure in place for care of patients with GHD transitioning from adolescence to adulthood. Most countries reported having at least one specialist centre for patients with AGHD. The main variations across the region included initial entry into healthcare systems, tests required to confirm AGHD diagnosis and medication reimbursement by health authorities. Most CEE countries relied on international society-led guidelines, while some countries have developed national guidelines. CONCLUSION: The CEE Adult Endocrinology Advisory Board meeting recognised considerable diversity in the care and patient pathways for AGHD across CEE countries. Additional work is needed to optimise care of patients with AGHD in the CEE region.
650    _2
$a dospělí $7 D000328
650    12
$a kritické cesty $7 D019091
650    _2
$a hypofyzární nanismus $x diagnóza $x genetika $x terapie $7 D004393
650    _2
$a lidský růstový hormon $x nedostatek $7 D019382
650    _2
$a lidé $7 D006801
650    _2
$a hypopituitarismus $x diagnóza $x genetika $x terapie $7 D007018
650    _2
$a směrnice pro lékařskou praxi jako téma $x normy $7 D017410
650    12
$a standardní péče $7 D059039
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Badiu, Corin $u "C. Davila" University of Medicine and Pharmacy, National Institute of Endocrinology, Bucharest, Romania.
700    1_
$a Bossowski, Artur $u Department of Pediatrics, Endocrinology, Diabetology with a Cardiology Unit, Medical University of Bialystok, Bialystok, Poland.
700    1_
$a Doknic, Mirjana $u Neuroendocrine Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Medical Faculty University of Belgrade, Serbia.
700    1_
$a Dzivite-Krisane, Iveta $u Children's University Hospital, Riga Stradin's University, Riga, Latvia.
700    1_
$a Hána, Václav $u 3(rd) Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Kollerova, Jana $u 5(th) Department of Internal Medicine, University Hospital of Comenius University Bratislava, Slovakia.
700    1_
$a Natchev, Emil $u Clinical Center of Endocrinology and Gerontology, Medical University, Sofia, Bulgaria.
700    1_
$a Pfeifer, Marija $u Faculty of Medicine, University of Ljubljana, Slovenia.
700    1_
$a Szũcs, Nikolette $u Semmelweis University, Budapest, Hungary.
700    1_
$a Hey-Hadavi, Juliana $u Pfizer, New York City, USA.
700    1_
$a Gomez, Roy $u Pfizer Innovative Health, Brussels, Belgium.
773    0_
$w MED00005163 $t Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society $x 1532-2238 $g Roč. 46-47, č. - (2019), s. 44-49
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31234055 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200525140555 $b ABA008
999    __
$a ok $b bmc $g 1525076 $s 1096274
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 46-47 $c - $d 44-49 $e 20190607 $i 1532-2238 $m Growth hormone & IGF research $n Growth Horm IGF Res $x MED00005163
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace